2014 promises to be a year of positive new initiatives for EURADIA and the diabetes research community more generally. As a result of sustained efforts by many in the research and advocacy world, diabetes is now gaining more attention, this being particularly evident at the recent kick-off meeting for the EU’s new Joint Action on chronic diseases in Madrid (CHRODIS-JA)
. We marked the welcome announcement of Horizon 2020 funding calls with our own, new quarterly funding bulletin which we hope will be of use. At a time when EU diabetes research funding is paramount, we will also continue to send out regular email funding alerts. 

Closer to home, we are pleased to announce that the ‘InterConnect’ project is now moving ahead apace. With the support of the European Commission, this 4-year scoping project aims to establish a global network that will facilitate the co-ordination of population research on the interaction between genetic and environmental factors in the causes of obesity and diabetes. EURADIA is specifically responsible for developing a sustainable and dynamic network of stakeholders and we will also be disseminating information about InterConnect to the research community, funders, stakeholders and the wider public. Please do visit InterConnect’s new website – your feedback is always most welcome.

We are also in the process updating the EURADIA Diamap Project and the Diamap Road Map Report, due to begin work this Spring. DIAMAP was originally a European Commission FP-7 funded project which undertook a wide survey of the European diabetes research landscape, from which expert opinion could identify gaps and highlight strengths in order to guide a Road Map strategy for diabetes research in Europe.


2014 European Commission Joint Action on Chronic Diseases
The kick off meeting of the Joint Action addressing chronic diseases (CHRODIS-JA) started on 29 January in Madrid. The aim of the 3 year ‘CHRODIS’ action is to help EU countries and regions to share good practice in addressing chronic disease and involves 38 organisations from 22 Members States, Norway and Iceland. As much of the burden caused by chronic disease is preventable, tacking these issues and ensuring that European health systems remain sustainable is essential. It is anticipated that the Action will result in a mechanism for the collection, validation, scaling up and transferring of good practices to address chronic diseases and multi-morbidity. Diabetes will be treated as a case study and will focus on multidisciplinary care, from primary prevention and treatment to national plans. The action is funded under the 2013 Plan, with 50% EC co-funding of €4.6 million and a total cost of €9.2 million. Find out more from DG Health here or contact the project co-ordinator Dr Juan E. Ries.
Equity Action: The Joint Action on Health Inequalities
Action to overcome health inequalities is required at EU, national, regional and local level, engaging a wide range of stakeholders across a range of policy areas. This Joint Action aims to strengthen the effectiveness of policy making at all levels. The Equity Action final conference took place on January 23 in Brussels, bringing together a wide range of stakeholders, including MEPs, experts in health inequality, policy makers. Speakers included Tonio Borg, EU Commissioner for Health, Zsuzsanna Jakab, Regional Director for Europe, World Health Organization and Paula Testori Coggi, Director-General for Health and Consumers, European Commission.

See EURADIA’s new funding bulletin for details of all Horizon 2020 and other relevant calls on the EURADIA website


Horizon 2020 was launched in December 2013, with funding for projects worth €15 billion over the first two years. This represents the first installment from the EC’s new research and innovation programme. As Máire Geoghegan-Quinn, European Commissioner for Research, Innovation and Science, pointed out at the Brussels press conference, this funding is welcomed by researchers who are finding national budgets squeezed; by business who need research and innovation in order to remain competitive in global markets and ultimately, by EU citizens. For the first time, the European Commission has given more clarity on the priorities and direction of EU research policy. Funding is focused primarily on the three key pillars of Horizon 2020, these being ‘excellent science’ (approx €3 billion), ‘industrial leadership’ (€1.8 billion) and ‘societal challenges’ (approx €2.8 billion).  More detailed information about the first calls and the 12 focus areas can be found here and at the EC’s participant portal. There are 2 specific calls relating to diabetes (see immediately below), but also many other funding calls relevant to our network.
Image source: European Commission

TOPIC: Global Alliance for Chronic Diseases: Prevention and treatment of type 2 diabetes
DEADLINE: 15 April 
SCOPE: Proposals must focus on type 2 diabetes. Proposals should generate new knowledge on interventions and their implementation for the prevention and treatment of type 2 diabetes in low and middle income countries, and in vulnerable populations in high income countries. Proposals must focus on existing approaches to prevention and control of type 2 diabetes rather than development of new treatments. Proposals may address prevention or treatment of specific complications of type 2 diabetes. See full call here.

TOPIC: Biomaterials for the treatment of diabetes mellitus: NMP-10-2014
DEADLINE: stage 1: 6 May 
DEADLINE stage 2: 7 October 
SCOPE: Proposals should develop one or more functional biomaterials for the long-term clinical efficacy of transplanted pancreatic islets, and the safe and reliable harvesting of cells from identified source(s), which facilitate highly sensitive identification/screening and sorting of isolated cells; allow for easy handling and safe storage of isolated cells and/or tissue engineering constructs; provide immunoprotection and facilitate construct grafting in target anatomical areas; as well as clinically-reflective in vitro models useful as indicators of long-term in vivo behaviour. See full call here.


Thrasher Research Fund - Spring 2014 cycle The purpose of the Thrasher Research Fund is to encourage the development of medical research in child health by awarding small grants to new researchers. The Fund is open to a number of research topics important to children's health. Both incidence and severity are considered when determining the significance of a problem being studied. Find out more at the grant website here.

Innovative Medicines Initiative 2 (IMI 2)
This initiative aims to develop next generation vaccines, medicines and treatments, such as new antibiotics. On 11 December 2013 IMI officially launched its 11th Call for proposals. The 11th Call includes eight topics. The full Call text and details of how to apply can be found on the 11th Call - Stage 1 webpage 
See here for topics
DEADLINE: 8 April 

6th Joint Call for European Research Projects on Rare Diseases (JTC 2014) (Innovative therapeutic approaches)
The aim of the call is to enable scientists in different countries to build an effective collaboration on a common interdisciplinary research project based on complementarities and sharing of expertise, with a clear translational approach. The research projects have to focus on the pre-clinical development of therapeutic approaches in suitable existing animal or cell model.

DEADLINE for full proposals: 26 May 

If you are in the process of putting together a consortium or seeking research partners, please do let us know and we will include your project details both here in our newsletter and on the EURADIA website.

Horizon 2020 Proposal - Towards tailored diabetes management
A European research group is currently working on a proposal intended for the Horizon 2020 topic ‘Understanding health, ageing and disease: determinants, risk factors and pathways’ (PHC-01-2014) under the call 'Personalising Health and Care'. The proposal builds on findings from a recent FP7-funded project, DISMEVAL (‘Developing and Validating Disease Management Evaluation Methods for European Healthcare Systems’). This showed that type 2 diabetes management in many European countries is still overly provider-driven and not sufficiently tailored to the health care needs, preferences and abilities of individual patients.
The aim of the proposed research is to develop instruments that facilitate a move from this ‘one-size-fits-all’ (disease management-like) approach to type 2 diabetes management to a more patient-centered, tailored care form that can lead to improved patient experience and has the potential to increase cost-effectiveness in practice by limiting the over, under and misuse of services. The instruments that the group intends to develop have the form of ‘patient profiles’, which combine the disease and patient features needed to stratify type 2 diabetes patients into clinically relevant subgroups, for whom optimal combinations of self-management support and professional-led care can be developed.

The research team are looking for European partners for this project. Please contact Dr Arianne Elissen, Professor Dr Bert Vrijhoef (National University of Singapore) or Professor Dr Nicolaas Schaper (Maastricht University Medical Centre) for more information.  


Date: 17 October 2014
Question: Amendment to the Law on Food Product Safety
Answer: Given by Mr Borg on behalf of the Commission (DG SANCO)

Date: 28 October 2013
Question: New devices for delivering drugs via light impulses
Answer: Given by Ms Geoghegan-Quinn on behalf of the Commission (DG Research and Innovation)

Date: 29 October 2013
Question: Sport and physical activity
Answer: Given by Ms Vassiliou on behalf of the Commission (DG Education and Culture)

Date: 4 November 2013
Question: Strokes affecting young people
Answer: Given by Mr Borg on behalf of the Commission (DG SANCO)

Date: 19 November 2013
Question: Encouraging cooperation and exchange of good practice for prevention, screening and control of diabetes
Answer: Given by Mr Borg on behalf of the Commission (DG SANCO)

Date: 20 November 2013
Question: Health: prevention as a means of easing the pressure on national healthcare system budgets
Answer: Given by Mr Borg on behalf of the Commission (DG SANCO)

Date: 28 November 2013
Question: Overweight children
Answer: Given by Mr Borg on behalf of the Commission (DG SANCO)

Date: 28 November 2013
Question: Type 2 diabetes - causes
Answer: Given by Mr Borg on behalf of the Commission (DG SANCO)

Date: 18 December 2013
Question: Potential links between perfluorinated compounds and type 2 diabetes
Answer: Commission response forthcoming

Date: 23 December 2013
Question: Gestational diabetes
Answer: Commission response forthcoming

Date: 10 January 2014
Question: Added sugars in food
Answer: Commission response forthcoming

Date: 31 January 2014
Question: Barriers to diabetes care in Europe
Answer: Commission response forthcoming


The LIBE committee (civil liberties, justice and home affairs) of the European Parliament have proposed 2 significant amendments (Articles 81 and 83) to the Data Protection Regulation. This proposed new Regulation would extend the scope of EU data protection law significantly. The original draft Regulation set out a proportionate mechanism for protecting privacy, while enabling health and scientific research to continue. However, serious and widespread concerns have been expressed that health and scientific research will be threatened if the amendments proposed by the LIBE committee are taken forward. A number of organisations argue that the benefits generated by scientific research involving personal data will be seriously hindered, if not rendered illegal. The Wellcome Trust has released a joint statement urging the Council of Ministers to maintain the original Commission text and to oppose the LIBE committee’s amendements both in the plenary vote and in trilogue negotiations. 


WHO report: Prevention and control of non-communicable diseases in the European Region: a progress report
This new report notes that while non-communicable diseases such as diabetes continue to be the leading cause of morbidity and mortality in Europe, innovation and achievements are visible, both in terms of disease prevention and control. The WHO nevertheless challenges Member States to scale up efforts to end the needless loss of life and productivity caused by non-communicable disease. Read the full report here.

Promoting health, preventing disease: Is there an economic case? The European Observatory on Health Systems and Policies, 4 November 2013
This new policy summary was presented in London, hosted by the Department of Health, inaugurating the newly established partnership with the Observatory, promoting and facilitating international knowledge transfer in health policy making. The publication is a joint collaboration between the Observatory, the WHO/Europe and the OCD and brings together evidence surrounding health promotion and non-communicable disease prevention. This policy summary argues that there is a substantial evidence base on the effectiveness of a wide range of actions targeted at risks to health including impacts of diet and patterns of physical activity, children's exposure to environmental harm and the protection of mental health. Read the full report here.

WHO European Ministerial Conference on the Prevention and Control of non-communicable Diseases 3-4 December 2013, Turkmenistan
The conference focused on three main issues:  non-communicable diseases (NCDs) and development, a tobacco-free Europe and national responses to NCDs. The Ashgabat Declaration was adopted at the conference, representing a commitment to Joint Action for NCD prevention and control in the European Region. Dr Pekka Puska (Director General at the National Institute for Health and Welfare, Finland), made particular reference to diabetes and her paper can be accessed via the link below. Read the full conference report here.

The Melbourne Declaration on Diabetes, 4 December 2013
The first ever forum for Parliamentary Champions for Diabetes has just been held in Melbourne, during the World Diabetes Congress, organised by the International Diabetes Federation. The parliamentarians released the Melbourne Declaration on Diabetes, agreed to unanimously, which established the Parliamentarians for Diabetes Global Network. This declaration is significant as is recognises the severity of the diabetes pandemic faced by all nations.  British MP Adrian Sanders was elected President of the first executive committee. Simon Busuttil, Malta’s opposition leader and Dr Rachel Nyamai MP from Kenya are Vice-Presidents. Tonio Borg, European Commissioner (DG SANCO) drew attention to the recently launched EU Joint Action to address chronic diseases and promote healthy ageing. Read the Melbourne Declaration on Diabetes here.

16th European Health Forum, Gastein, October 2-4, 2014
Considerable attention was paid to diabetes at the conference, since patients living with chronic diseases are often confronted with severe societal challenges due to the lack of existing patient-centred care. Diabetes was the focus of Sandra Stiefel’s workshop on patient-centred care, as less than half of all diabetes patients achieve control of their diabetes due to the lack of a real model of chronic care. Austria, for example, is the European country with the highest uncontrolled hospital admissions for diabetes, which is four times the rate of Italy. Søren Eik Skovlund (Novo Nordisk) presented the results of the DAWN 2 study that analysed and identified barriers preventing the implementation of more patient-centered care among people living with diabetes. Italian researcher and diabetologist Marco Comaschi drew particular attention to the needs of family members of those living with diabetes, and the need to raise their levels of awareness and knowledge about the disease. Annemarie Bevers (IDF Europe) also highlighted that psychological counselling should be part of a diabetic person’s treatment. Read the full conference report here.

IDF Europe study on Access to Diabetes Treatment in Europe.  IDF  Europe recently published the first report of its kind to highlight disparities accessing medicines and devices for diabetes care across 47 countries. Based on over 1,150 responses to questionnaires, interviews and desk research, the study intends to provide evidence to stakeholders and policy makers about the challenges faced by people living with diabetes when accessing treatment. The study explores its themes via 5 sub-regional analyses plus detailed country profiles. Download the full survey here.



European Forum for Good Clinical Practice workshop
'Striving for good clinical practice in IITs'
26-27 February, Brussels
Draft programme here

‘Health in Europe, making it fairer'
18 March, Brussels
Registration deadline: 4 March
Draft programme here

DZD workshops 2014
Retreat for young scientists
24-25 March, Tübingen

The 2014 EU summit on chronic diseases: Addressing the medical, social and economic burden of chronic diseases in the EU
3-4 April, Brussels
Read the draft programme here
Registration deadline: 17 February

CEBR Annual Meeting
3-4 April 2013, Coimbra, Portugal

13th International Primary Care Diabetes Europe Conference 2014:
Diabetes Education in Multimorbidity and Hypoglycaemic Management

23-24 May 2014, Barcelona
Deadline for abstracts: 3 March
Deadline for online registration: 5 May

3rd International Conference on Prehypertension, Hypertension and Cardio Metabolic Syndrome
27-30 March 2014, Warsaw, Poland
Deadline for registration: 13 March

19th Fend Annual Conference
12-13 September, Vienna
More details forthcoming, see here

50th EASD Annual Meeting
15-19 September, Vienna
Abstract submission deadline: 1 April
Early registration deadline:1 July


ESPE Dublin 53rd Annual Meeting
18th-20 September, Dublin
Early bird registration: 23 April 
Standard registration: 23 July

EUPATI 2014 workshop: reaching the general public on medicines development
2 April, Warsaw
More details forthcoming, see here

 European Health Forum, Gastein

1-3 October, 2014
More details forthcoming, see here


Send us your news

EURADIA publishes meeting and deadline dates on its website (under News – Diary Dates) and will include relevant reports and articles in its newsletter.  Contact

Follow us @EURADIAnews

EURADIA: The Alliance for European Diabetes Research

EURADIA is an alliance of non-profit organisations and health care companies working together to further the cause of diabetes research. EURADIA has existed since 2003 and as a registered non-profit organisation in Germany since 2007 and in the UK since 2013. EURADIA serves as a visible and effective advocate for diabetes research at the highest levels, representing the best interests of both academia and the healthcare industry. The European Commission and Parliament recognise EURADIA as a unique alliance and an important facilitator of public-private partnerships. 


Follow on Twitter | Forward to Friend 
Copyright ©  2014 EURADIA All rights reserved


Non-Profit-Association, registered at the County Court Düsseldorf. Registry Number: VR 9885
Registered in the UK as a company limited by guarantee, registry number 8608154 and as registered charity number 1154726
unsubscribe from this list | update subscription preferences